FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs

The Food and Drug Administration (FDA) ‌on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.  Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an “eye stroke,” is a rare condition…